Читать книгу The SAGE Encyclopedia of Stem Cell Research - Группа авторов - Страница 249

Advanced breast cancers are often hard to treat, so researchers are always looking for newer drugs. A drug class has been developed that targets cancers caused by BRCA mutations. This class of drugs is called PARP inhibitors, and they have shown promise in clinical trials treating breast, ovarian, and prostate cancers that had spread and were resistant to other treatments. Further studies are being done to see if this drug can help patients without BRCA mutations.